Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy

Abstract

Tumor immunotherapy with IL-18 can significantly augment the killing fraction of phase-specific chemotherapeutic drugs and provide survival benefit. The safety profile of IL-18 and its positive interactions with select anticancer chemotherapeutic agents strongly supports the clinical investigation of this combinatorial approach.